Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 03'rd Oct 2024
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
05:44am, Sunday, 29'th Sep 2024
Cathie Wood invests in businesses that are risky, but with a lot of upside. Intellia Therapeutics has a couple of key readouts coming up.
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
04:40pm, Wednesday, 25'th Sep 2024
Intellia Therapeutics is pioneering in-vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster st
3 'Repeatable' Biotech Trades
12:46pm, Wednesday, 25'th Sep 2024
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 03'rd Sep 2024
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
12:35pm, Friday, 09'th Aug 2024
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
3 Gene Editing Stocks with Potential to Transform Medicine
10:19am, Friday, 09'th Aug 2024
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disord
Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript
11:29am, Thursday, 08'th Aug 2024
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations & Corporate Communicatio
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
09:56am, Thursday, 08'th Aug 2024
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago.
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 08'th Aug 2024
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
The 3 Best Cathie Wood Stocks to Buy in August 2024
12:48pm, Tuesday, 06'th Aug 2024
As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular in
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
06:03am, Saturday, 03'rd Aug 2024
The future is here
